Skip to main content
. Author manuscript; available in PMC: 2015 Nov 17.
Published in final edited form as: Exp Hematol. 2013 Feb 19;41(6):547–557.e2. doi: 10.1016/j.exphem.2013.02.008

Figure 6.

Figure 6

APO866 inhibits growth of H929 cells in the SCID-rab model. SCID-rab mice engrafted with the luciferase-expressng H929 MM cell line and treated with saline (CONT; n = 6) or APO866 (20 mg/kg, twice a day for 5 days/week, subcutaneously; n = 8) for 3 weeks. (A) Live-animal bioluminescence analysis at the indicated time points shows inhibition of tumor growth by APO866 (B) Representative photographs of five hosts from each group show the bioluminescence intensity of tumors in the implanted bones before initiation of treatment (Pre-Rx) and at the end of the experiment (Final). (C) Circulating levels of human immunoglobulins (Ig) at the end of the experiment indicate a reduced tumor burden in APO866-treated hosts compared with control hosts (CONT).